These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1503 related items for PubMed ID: 29798776
1. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents. Alfonso F, Pérez-Vizcayno MJ, Cuesta J, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Cequier A, Velázquez M, Moreno R, Mainar V, Domínguez A, Moris C, Molina E, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández-Pérez C, RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). JACC Cardiovasc Interv; 2018 May 28; 11(10):981-991. PubMed ID: 29798776 [Abstract] [Full Text] [Related]
3. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials. Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Melgares R, Mainar V, Moreno R, Domínguez A, Sanchís J, Bethencourt A, Moreu J, Cequier A, Martí V, Otaegui I, Bastante T, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C, under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology. Circ Cardiovasc Interv; 2016 Jul 28; 9(7):. PubMed ID: 27412868 [Abstract] [Full Text] [Related]
5. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial. Claessen BE, Henriques JPS, Vendrik J, Boerlage-van Dijk K, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, Piek JJ, Baan J. Catheter Cardiovasc Interv; 2019 Feb 01; 93(2):216-221. PubMed ID: 30232824 [Abstract] [Full Text] [Related]
6. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial. Baan J, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, de Winter RJ, Koch KT, Sjauw KD, Beijk MA, Vis MM, Wykrzykowska JJ, Piek JJ, Tijssen JGP, Henriques JPS. JACC Cardiovasc Interv; 2018 Feb 12; 11(3):275-283. PubMed ID: 29413242 [Abstract] [Full Text] [Related]
7. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C, RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. J Am Coll Cardiol; 2014 Apr 15; 63(14):1378-86. PubMed ID: 24412457 [Abstract] [Full Text] [Related]
8. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C, RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). J Am Coll Cardiol; 2015 Jul 07; 66(1):23-33. PubMed ID: 26139054 [Abstract] [Full Text] [Related]
9. Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study. Cuesta J, Pérez-Vizcayno MJ, García Del Blanco B, Bosa F, Pérez de Prado A, Rumoroso JR, Romaguera R, Gutiérrez H, García Touchard A, López-Mínguez JR, Trillo R, de la Torre Hernández JM, Moreno R, Velázquez M, Moris C, Kockar MJ, Jiménez-Quevedo P, Bastante T, Del Val D, Rivero F, Alfonso F. JACC Cardiovasc Interv; 2024 Aug 12; 17(15):1825-1836. PubMed ID: 39142758 [Abstract] [Full Text] [Related]
10. Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials). Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, Masotti M, López-Minguez JR, Iñiguez A, Zueco J, Velazquez M, Cequier A, Lázaro-García R, Martí V, Moris C, Urbano-Carrillo C, Bastante T, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C, Restenosis Intra-Stent: Drug-Eluting Balloon vs Everolimus-Eluting Stent (RIBS-IV and V Studies) Investigators (Under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). Am J Cardiol; 2016 Feb 15; 117(4):546-554. PubMed ID: 26725102 [Abstract] [Full Text] [Related]
11. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study). Moscarella E, Tanaka A, Ielasi A, Cortese B, Coscarelli S, De Angelis MC, Piraino D, Latib A, Grigis G, Bianchi R, Buccheri D, Calabrò P, Tespili M, Silva Orrego P, Colombo A, Varricchio A. Catheter Cardiovasc Interv; 2018 Oct 01; 92(4):668-677. PubMed ID: 29356269 [Abstract] [Full Text] [Related]
12. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study. Alfonso F, Cuesta J, Pérez-Vizcayno MJ, García Del Blanco B, Rumoroso JR, Bosa F, Pérez de Prado A, Masotti M, Moreno R, Cequier A, Gutiérrez H, García Touchard A, López-Mínguez JR, Zueco J, Martí V, Velázquez M, Morís C, Bastante T, García-Guimaraes M, Rivero F, Fernández C, Interventional Cardiology Working Group of the Spanish Society of Cardiology. JACC Cardiovasc Interv; 2017 Sep 25; 10(18):1841-1851. PubMed ID: 28866036 [Abstract] [Full Text] [Related]
13. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study. Pleva L, Kukla P, Zapletalova J, Hlinomaz O. Catheter Cardiovasc Interv; 2018 Nov 15; 92(6):E416-E424. PubMed ID: 30019843 [Abstract] [Full Text] [Related]
14. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Basavarajaiah S, Naganuma T, Latib A, Sticchi A, Ciconte G, Panoulas V, Chieffo A, Montorfano M, Carlino M, Colombo A. Catheter Cardiovasc Interv; 2016 Oct 15; 88(4):522-528. PubMed ID: 26715370 [Abstract] [Full Text] [Related]
16. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis. Almalla M, Schröder J, Pross V, Marx N, Hoffmann R. Catheter Cardiovasc Interv; 2014 May 01; 83(6):881-7. PubMed ID: 23765557 [Abstract] [Full Text] [Related]
17. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty. Oh PC, Suh SY, Kang WC, Lee K, Han SH, Ahn T, Shin EK. Korean J Intern Med; 2016 May 01; 31(3):501-6. PubMed ID: 26951915 [Abstract] [Full Text] [Related]
18. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. Pleva L, Kukla P, Zapletalova J, Hlinomaz O. BMC Cardiovasc Disord; 2017 Jun 26; 17(1):168. PubMed ID: 28651572 [Abstract] [Full Text] [Related]